Robert Stuart to Leukemia, Myelogenous, Chronic, BCR-ABL Positive
This is a "connection" page, showing publications Robert Stuart has written about Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Connection Strength
0.407
-
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Adv. 2018 11 13; 2(21):2922-2936.
Score: 0.155
-
Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood. 2011 Jun 02; 117(22):5941-52.
Score: 0.092
-
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin Cancer Res. 2011 Mar 01; 17(5):1140-6.
Score: 0.090
-
Autologous bone marrow transplantation for leukemia. Semin Oncol. 1993 Oct; 20(5 Suppl 6):40-54.
Score: 0.027
-
Cellular glutathione as a protective agent against 4-hydroperoxycyclophosphamide cytotoxicity in K-562 cells. Cancer Chemother Pharmacol. 1990; 26(6):397-402.
Score: 0.021
-
Hematopoietic stem cell origin of human fibroblasts: cell culture studies of female recipients of gender-mismatched stem cell transplantation and patients with chronic myelogenous leukemia. Exp Hematol. 2009 Dec; 37(12):1464-71.
Score: 0.021